Drugs for treating inflammatory bowel disease
A pharmaceutical composition with a specific HMGB1 fragment peptide addresses the limitations of current IBD treatments by effectively reducing weight loss and mucosal damage in animal models, offering a safer and more effective alternative.
Patent Information
- Application Number
- JP2023114129
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-08
- Filing Date
- 2023-07-12
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2038-11-30
AI Technical Summary
Current treatments for inflammatory bowel disease (IBD) are inadequate, with existing drugs often having limited efficacy and significant side effects, necessitating the development of a more effective and safer therapeutic agent.
A pharmaceutical composition containing a specific HMGB1 fragment peptide, including sequences with specific amino acid modifications, is used to suppress weight loss and mucosal damage in IBD, targeting both ulcerative colitis and Crohn's disease.
The HMGB1 fragment peptide effectively reduces weight loss and mucosal damage in animal models of IBD, demonstrating potential as a safer and more effective treatment option compared to existing therapies.
Smart Images

Figure 0007590724000001 
Figure 0007590724000002 
Figure 0007590724000003
Abstract
Description
[Technical field]
[0001] The present application relates to a pharmaceutical composition for the prevention and / or treatment of inflammatory bowel disease, comprising a fragment peptide of High mobility group box 1 (HMGB1) protein. [Background technology]
[0002] Inflammatory bowel disease (IBD) is an intractable disease in which chronic inflammation and / or ulcers occur in the intestinal mucosa, and representative examples include ulcerative colitis and Crohn's disease. The cause of IBD has not yet been fully elucidated, but it is thought to be caused by a complex combination of genetic factors and various environmental factors that cause immune system abnormalities. However, there is currently no cure for IBD, and since remission and relapse often occur repeatedly, long-term medical management is required.
[0003] As therapeutic agents for inflammatory bowel disease, 5-aminosalicylic acid preparations, corticosteroid preparations, immunosuppressants, biological agents (e.g., anti-TNF-α antibodies and anti-α4β7 integrin antibodies), etc. are used, but there are cases where sufficient effects are not obtained. Furthermore, in terms of side effects, there are problems such as nausea, fever, abdominal pain, anemia, interstitial nephritis, and liver dysfunction caused by 5-aminosalicylic acid preparations; insomnia, osteoporosis, adrenal insufficiency, impaired glucose tolerance, and elevated blood pressure caused by corticosteroid preparations; and renal dysfunction, liver dysfunction, leukopenia, and elevated blood pressure caused by immunosuppressants, and there is room for improvement. Therefore, there is a need for the development of a more effective and safer type of therapeutic agent for inflammatory bowel disease that is different from existing therapeutic agents. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO2012 / 147470 [Patent Document 2] WO2014 / 065347 [Patent Document 3] WO2014 / 065348 Summary of the Invention [Problem to be solved by the invention]
[0005] The present application aims to provide a novel medicament that is effective in treating inflammatory bowel disease. [Means for solving the problem]
[0006] The present inventors have searched for substances effective in treating inflammatory bowel disease and found that an HMGB1 fragment peptide having a specific amino acid sequence exhibits the effect of suppressing weight loss and the effect of suppressing shortening of the large intestine and mucosal damage in an animal model of inflammatory bowel disease. Therefore, the present application provides a pharmaceutical composition for preventing and / or treating inflammatory bowel disease, which contains the specific HMGB1 fragment peptide.
[0007] That is, the present application provides the following: [1] A pharmaceutical composition for preventing and / or treating inflammatory bowel disease, comprising a substance (hereinafter referred to as "Substance A") according to any one of (a) to (c) below: (a) an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide comprising an amino acid sequence in which one or more amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO:1; and (c) A peptide comprising an amino acid sequence having about 80% or more sequence identity with the amino acid sequence set forth in SEQ ID NO:1. [2] The pharmaceutical composition according to [1], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [3] The pharmaceutical composition according to [2], wherein the non-specific inflammatory bowel disease is ulcerative colitis. [4] The pharmaceutical composition according to [2], wherein the nonspecific inflammatory bowel disease is Crohn's disease. [5] A pharmaceutical composition for suppressing weight loss or intestinal mucosal damage in a patient with inflammatory bowel disease, comprising substance A. [6] The pharmaceutical composition according to [5], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [A1] A method for preventing and / or treating inflammatory bowel disease, comprising administering an effective amount of substance A to a subject. [A2] The method according to [A1], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [A3] The method according to [A2], wherein the nonspecific inflammatory bowel disease is ulcerative colitis. [A4] The method according to [A2], wherein the non-specific inflammatory bowel disease is Crohn's disease. [A5] A method for inhibiting weight loss or damage to the intestinal mucosa in a patient suffering from inflammatory bowel disease, comprising the step of administering an effective amount of substance A to said patient. [A6] The method according to [A5], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [B1] Substance A for use in the prevention and / or treatment of inflammatory bowel disease. [B2] Substance A described in [B1], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [B3] The substance A described in [B2], wherein the non-specific inflammatory bowel disease is ulcerative colitis. [B4] The substance A described in [B2], wherein the non-specific inflammatory bowel disease is Crohn's disease. [B5] Substance A for use in reducing weight loss or inhibiting intestinal mucosal damage in patients with inflammatory bowel disease. [B6] Substance A described in [B5], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [C1] 2. Use of substance A in the manufacture of a medicament for the prevention and / or treatment of inflammatory bowel disease. [C2] The use described in [C1], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [C3] The use described in [C2], wherein the non-specific inflammatory bowel disease is ulcerative colitis. [C4] The use according to [C2], wherein the non-specific inflammatory bowel disease is Crohn's disease. [C5] Use of substance A in the manufacture of a medicament for inhibiting weight loss or intestinal mucosal damage in a patient with inflammatory bowel disease. [C6] The use described in [C5], wherein the inflammatory bowel disease is non-specific inflammatory bowel disease. [Brief description of the drawings]
[0008] [Figure 1] This is a graph showing changes in mouse body weight (*** p<0.001, **** p<0.0001). In the graph, "Water" indicates normal mice, "DSS+saline" indicates the control group, and "DSS+1-44" indicates the HMGB1 peptide (1-44) administration group. On the horizontal axis, the number of days indicates the number of days after the start of drinking dextran sulfate sodium (DSS) aqueous solution, and triangles indicate the administration days for the control group and the HMGB1 peptide (1-44) administration group. [Diagram 2] The figures show photographs of the large intestine excised from mice 9 days after they started drinking DSS aqueous solution, and a graph showing the colon length (*p<0.05, **p<0.01). [Diagram 3] This is a graph showing the expression levels of inflammatory cytokines in the large intestine on day 9 after starting to drink DSS aqueous solution (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). [Figure 4]This is a graph showing changes in mouse body weight (**** p<0.0001). In the graph, "Water" indicates normal mice, "DSS+saline" indicates the control group, and "DSS+1-44" indicates the HMGB1 peptide (1-44) administration group. On the horizontal axis, the number of days indicates the number of days after the mice started drinking DSS aqueous solution, and the triangles indicate the administration days for the control group and the HMGB1 peptide (1-44) administration group. [Diagram 5] The figures show photographs of the large intestine excised from mice 10 days after they started drinking DSS aqueous solution, and a graph showing the length of the large intestine (*p<0.05, **p<0.01). [Figure 6] 1 shows images showing the results of HE staining of colon tissue on day 10 after starting to drink a DSS aqueous solution. [Figure 7] This is a graph showing changes in mouse body weight (**** p<0.0001). In the graph, "Water" indicates normal mice, "DSS+PI5 saline" indicates the control group, and "DSS+PI5 1-44" indicates the HMGB1 peptide (1-44) administration group. The number of days on the horizontal axis indicates the number of days after the mice started drinking DSS aqueous solution. [Figure 8] The figures show photographs of the large intestine excised from mice 10 days after they started drinking DSS aqueous solution, and a graph showing the colon length (* p<0.05, ** p<0.01, *** p<0.001). [Figure 9] This is a graph showing changes in mouse body weight (**** p<0.0001). In the graph, "Water" indicates normal mice, "DSS+PBS" indicates the control group, and "DSS+MSCs" indicates the MSC-administered group. On the horizontal axis, the number of days indicates the number of days after the mice started drinking DSS aqueous solution, and the triangles indicate the administration days for the control group and the MSC-administered group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The present application provides a pharmaceutical composition for the prevention and / or treatment of inflammatory bowel disease, which comprises an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO:1.
[0010] Inflammatory bowel disease (hereinafter also referred to as IBD) in the present application includes diseases with unknown causes (non-specific inflammatory bowel disease) and diseases with clear association with causes (specific inflammatory bowel disease). Non-specific inflammatory bowel disease includes, but is not limited to, ulcerative colitis, Crohn's disease, and intestinal Behcet's disease. Specific inflammatory bowel disease includes, but is not limited to, infectious enteritis, drug-induced enteritis, ischemic enteritis, intestinal tuberculosis, etc. In one embodiment, the inflammatory bowel disease of the present application is non-specific inflammatory bowel disease. In a further embodiment, the non-specific inflammatory bowel disease of the present application is ulcerative colitis or Crohn's disease. In another embodiment, the non-specific inflammatory bowel disease of the present application is ulcerative colitis. In another further embodiment, the non-specific inflammatory bowel disease of the present application is Crohn's disease.
[0011] Ulcerative colitis is an inflammatory disease of unknown cause that causes erosions and ulcers in the mucous membrane of the large intestine. The main symptoms are bloody stools, bloody mucus in the stool, diarrhea or bloody diarrhea, abdominal pain, and are often accompanied by fever and weight loss.
[0012] Crohn's disease is a chronic inflammatory disease of unknown etiology that causes granulomatous inflammatory lesions accompanied by ulcers and fibrosis in the digestive tract. The main symptoms are abdominal pain, diarrhea, weight loss, and fever. Intestinal complications such as fistulas and stenosis, and extraintestinal complications such as anemia, arthritis, iritis, erythema nodosum, and anal lesions may also occur.
[0013] In this application, the term "pharmaceutical composition" is used interchangeably with "medicament," "drug," or "pharmaceutical composition."
[0014] The present application also provides a pharmaceutical composition for suppressing weight loss or intestinal mucosal damage in a patient with inflammatory bowel disease, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1. In one embodiment, the pharmaceutical composition of the present application is used for suppressing colonic mucosal damage in a patient with inflammatory bowel disease.
[0015] In the present application, an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 means a peptide consisting of a part of the HMGB1 protein and comprising the amino acid sequence set forth in SEQ ID NO: 1. Such a peptide can be obtained as a recombinant by incorporating DNA encoding the peptide into an appropriate expression system, or can be artificially synthesized.
[0016] In the present application, examples of HMGB1 protein include, but are not limited to, a protein comprising the amino acid sequence set forth in SEQ ID NO: 2 and a protein encoded by DNA comprising the base sequence set forth in SEQ ID NO: 3.
[0017] In the present application, an example of an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO:1 is an HMGB1 fragment peptide consisting of the amino acid sequence set forth in SEQ ID NO:1, but is not limited to this.
[0018] In the pharmaceutical compositions of the present application, instead of or together with the HMGB1 fragment peptide containing the amino acid sequence set forth in SEQ ID NO: 1, it is also possible to use a peptide that contains an amino acid sequence in which one or more amino acid residues in the amino acid sequence set forth in SEQ ID NO: 1 have been modified (substituted, deleted, inserted or added), and that is functionally equivalent to the HMGB1 fragment peptide containing the amino acid sequence set forth in SEQ ID NO: 1. Examples of such peptides include, but are not limited to, the following: i) a peptide comprising an amino acid sequence in which one or more (e.g., 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2) amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1; ii) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more (for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2) amino acids have been substituted, deleted, inserted or added; iii) a peptide comprising an amino acid sequence having about 80% or more, for example about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more, sequence identity to the amino acid sequence set forth in SEQ ID NO:1; iv) A peptide consisting of an amino acid sequence having a sequence identity of about 80% or more, for example about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more to the amino acid sequence set forth in SEQ ID NO:1.
[0019] An effective amount of the peptide of the present application or a pharmaceutical composition containing the same (hereinafter referred to as peptide, etc.) is administered to a subject for the treatment or prevention of a disease or condition described herein.
[0020] As used herein, an effective amount refers to an amount sufficient to treat or prevent a disease or condition as described herein. As used herein, treating includes, but is not limited to, reducing, delaying, preventing, ameliorating, remission, curing, curing, etc. As used herein, preventing includes, but is not limited to, reducing, delaying, preventing, etc.
[0021] The subject in the present application is not particularly limited, and includes mammals, birds, fish, etc. Mammals include humans and non-human animals, such as, but not limited to, humans, mice, rats, monkeys, pigs, dogs, rabbits, hamsters, guinea pigs, horses, sheep, whales, etc. In the present application, the term "subject" is used interchangeably with "patient," "individual," and "animal."
[0022] There are no limitations on the site of administration of the peptides, etc. of the present application, and the peptides, etc. of the present application can exert their effects regardless of the site of administration, such as the site where symptoms of inflammatory bowel disease appear or in the vicinity thereof, a site different from these (sites other than these), a site away from the site where symptoms of inflammatory bowel disease appear, a site distal to the site where symptoms of inflammatory bowel disease appear, or a site distal and ectopic to the site where symptoms of inflammatory bowel disease appear.
[0023] Furthermore, the peptides and the like of the present application can exert their effects when administered to any tissue, such as tissue other than the tissue in which symptoms of inflammatory bowel disease appear (e.g., the digestive tract), tissue distant from the tissue in which symptoms of inflammatory bowel disease appear, tissue distal to the tissue in which symptoms of inflammatory bowel disease appear, or tissue distal and ectopic to the tissue in which symptoms of inflammatory bowel disease appear.
[0024] Methods for administering the peptides and the like of the present application include oral administration or parenteral administration, and parenteral administration methods include, but are not limited to, intravascular administration (intraarterial administration, intravenous administration, etc.), intramuscular administration, subcutaneous administration, intradermal administration, intraperitoneal administration, nasal administration, pulmonary administration, transdermal administration, etc. In addition, the peptides and the like of the present application can be administered systemically or locally (for example, subcutaneously, intradermally, on the skin surface, on the eyeball or palpebral conjunctiva, on the nasal mucosa, in the oral cavity and in the digestive tract mucosa, on the vagina or in the uterus mucosa, or at an injured site, etc.) by injection, for example, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, etc.
[0025] Moreover, instead of the peptides of the present application, cells that secrete the peptides of the present application, vectors for gene therapy into which DNA encoding the peptides has been inserted, and pharmaceutical compositions containing these can also be used.
[0026] In addition, the administration method can be appropriately selected depending on the age and symptoms of the patient. When administering the peptide of the present application, the dosage can be selected, for example, in the range of 0.0000001 mg to 1000 mg per kg of body weight per administration. Alternatively, the dosage can be selected, for example, in the range of 0.00001 to 100000 mg / body per patient. When administering cells secreting the peptide of the present application or a gene therapy vector into which DNA encoding the peptide is inserted, the amount of the peptide can be administered within the above range. However, the pharmaceutical composition of the present application is not limited to these dosages.
[0027] The pharmaceutical composition of the present application can be formulated according to a conventional method (e.g., Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, USA), and may contain pharma- ceutically acceptable carriers and additives. Examples of such carriers include, but are not limited to, surfactants, excipients, colorants, flavorings, preservatives, stabilizers, buffers, suspending agents, isotonicity agents, binders, disintegrants, lubricants, flow enhancers, and flavoring agents. Other commonly used carriers can be used as appropriate. Specific examples of such carriers include light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglycerides, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethyl cellulose, corn starch, and inorganic salts.
[0028] All prior art documents cited in this specification are hereby incorporated by reference.
[0029] The present invention is further illustrated by the following non-limiting examples. EXAMPLES
[0030] Example 1 Efficacy of HMGB1 fragment peptides for inflammatory bowel disease (1)
[0031] (1) Materials and methods i) Drug Preparation Dextran sodium sulfate (DSS) (molecular weight 5,000-6,000, Nacalai Tesque, catalog number 10930-94) was dissolved in water to prepare a 3% (w / v) DSS aqueous solution. A peptide consisting of amino acid residues 1-44 (SEQ ID NO: 1) of human HMGB1 protein was chemically synthesized by solid-phase method. Hereinafter, this HMGB1 fragment peptide is referred to as HMGB1 peptide (1-44), and is abbreviated to "1-44" in the drawings corresponding to the examples.
[0032] ii) Creation of inflammatory bowel disease (IBD) model mice Colitis was induced in C57BL / 6 mice (8-10 weeks old, male, weighing approximately 20 g) by allowing them to freely drink 3% DSS aqueous solution instead of purified water (RO water) (they continued to drink DSS aqueous solution until the time of removal of the large intestine). Mice that were allowed to freely drink purified water (RO water) (hereinafter referred to as "normal mice") were used as control subjects.
[0033] iii) Administration of peptides The IBD model mice prepared as described above were divided into an HMGB1 peptide (1-44) administration group (n=3) and a control group (n=3). The test substance was administered by intravenously injecting 200 μL / mouse of HMGB1 peptide (1-44) solution adjusted to a concentration of 0.5 mg / mL using saline as a solvent on the 6th and 7th days after the start of drinking the DSS aqueous solution (peptide dose: 5 mg / kg). In the control group, saline was intravenously injected at 200 μL / mouse on the 6th and 7th days after the start of drinking the DSS aqueous solution (physiological solution). No substance was administered to normal mice (n=3). In the following, "Xth day after the start of drinking the DSS aqueous solution" is abbreviated to "Xth day of DSS drinking".
[0034] iv) Evaluation of the effect of peptide administration The mice were weighed daily from the start of drinking the DSS aqueous solution until the removal of the large intestine. On the ninth day after drinking the DSS aqueous solution, the large intestine was removed from the mice and the length of the colon was measured. mRNA was extracted from the distal part of the removed colon close to the anus, and the expression levels of inflammatory cytokines (TNF-α, IL-1β, IL-6) were analyzed by quantitative PCR.
[0035] (2) Results i) Weight change The changes in mouse body weight over the test period are shown in Figure 1 (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44)-administered group). The body weight of the IBD model mice in the control group decreased over the days, and was significantly smaller than that of the normal mice on the 9th day of drinking DSS water. In contrast, in the HMGB1 peptide (1-44)-administered group, the weight that had initially decreased recovered after administration of the peptide, and was significantly larger than that of the control group on the 9th day of drinking DSS water.
[0036] ii) Colon length As shown in Figure 2, under conditions in which the colon length of the control group of IBD model mice was significantly shorter than that of normal mice, the colon length of the HMGB1 peptide (1-44) administration group was significantly longer than that of the control group (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44) administration group). These results indicate that colon shortening in DSS-induced colitis, a model of IBD, was suppressed by administration of HMGB1 peptide (1-44).
[0037] iii) Inflammatory cytokines Figure 3 shows the expression levels of inflammatory cytokines in the large intestine on day 9 of DSS drinking (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44)-administered group). In the control group of IBD model mice, the expression of TNF-α, IL-1β, and IL-6 was significantly higher than in normal mice. On the other hand, the expression of TNF-α, IL-1β, and IL-6 in the HMGB1 peptide (1-44)-administered group was significantly lower than in the control group. These results indicate that the expression of inflammatory cytokines in DSS-induced enteritis, a model of IBD, was suppressed by administration of HMGB1 peptide (1-44).
[0038] Example 2 Efficacy of HMGB1 fragment peptides for inflammatory bowel disease (2)
[0039] (1) Materials and methods i) Drugs and Mice The preparation of the DSS aqueous solution and the HMGB1 peptide (1-44), and the generation of inflammatory bowel disease model mice were carried out in the same manner as in Example 1.
[0040] ii) Administration of peptides IBD model mice prepared as described in Example 1 were divided into an HMGB1 peptide (1-44) administration group (n=3) and a control group (n=3). The test substance was administered by intravenously injecting 200 μL / mouse of HMGB1 peptide (1-44) solution adjusted to a concentration of 0.5 mg / mL using saline as a solvent on days 1, 3, 5, and 7 of DSS drinking water (peptide dose: 5 mg / kg). In the control group, saline was intravenously injected at 200 μL / mouse on days 1, 3, 5, and 7 of DSS drinking water. No substance was administered to normal mice (n=3).
[0041] iii) Evaluation of the effect of peptide administration The mice were weighed daily from the start of drinking the DSS aqueous solution until the removal of the large intestine. On the 10th day after drinking the DSS aqueous solution, the large intestine was removed from the mice and the length of the large intestine was measured. The distal part of the removed large intestine near the anus was used to prepare tissue sections of the intestinal tract and stained with hematoxylin and eosin (HE).
[0042] (2) Results i) Weight change The changes in mouse body weight over the test period are shown in Figure 4 (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44)-administered group). The body weight of the IBD model mice (control group and HMGB1 peptide (1-44)-administered group) decreased over the days, and was significantly smaller than that of normal mice on the 10th day of drinking DSS water. In the HMGB1 peptide (1-44)-administered group, weight loss was suppressed compared to the control group, and body weight on the 10th day of drinking DSS water was significantly greater than that of the control group.
[0043] ii) Colon length As shown in Figure 5, under conditions in which the colon length of the control IBD model mice was significantly shorter than that of normal mice, the colon length of the HMGB1 peptide (1-44) administration group was significantly longer than that of the control group (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44) administration group). These results indicate that colon shortening in DSS-induced colitis, an IBD model, was suppressed by administration of HMGB1 peptide (1-44).
[0044] iii) mucosal tissue Figure 6 shows HE staining images of colonic tissue on the 10th day after drinking DSS water (see "Water" for normal mice, "DSS+saline" for the control group, and "DSS+1-44" for the HMGB1 peptide (1-44)-administered group). Whereas mucosal tissue was damaged in the control IBD model mice, mucosal tissue damage was suppressed in the HMGB1 peptide (1-44)-administered group. These results indicate that administration of HMGB1 peptide (1-44) suppressed damage to colonic mucosal tissue in DSS-induced colitis, an IBD model.
[0045] Example 3 Efficacy of HMGB1 fragment peptides for inflammatory bowel disease (3)
[0046] (1) Materials and methods i) Drugs and mice The preparation of the DSS aqueous solution and the HMGB1 peptide (1-44), and the generation of inflammatory bowel disease model mice were carried out in the same manner as in Example 1.
[0047] ii) Preparation of peptide-containing hydrogels Bioabsorbable hydrogel (MedGel) cut into pieces of approximately 5 mm x 5 mm (登録商標) 20 μL of HMGB1 peptide (1-44) solution adjusted to a concentration of 5 μg / μL using saline as a solvent was added dropwise to hydrogel PI5 (Medgel Co., Ltd.), which was then allowed to stand on ice for 30 minutes and used for implantation into mice in the HMGB1 peptide (1-44) administration group. Following the same procedure, a hydrogel containing saline instead of the HMGB1 peptide (1-44) solution was used for implantation into mice in the control group.
[0048] iii) Administration of peptides IBD model mice prepared as described in Example 1 were divided into an HMGB1 peptide (1-44) administration group (n=3) and a control group (n=3). Test substances were administered by implanting the hydrogel containing HMGB1 peptide (1-44) solution prepared as described above into the backs of the mice one day before they started drinking the DSS aqueous solution. Saline-containing hydrogel prepared as described above was implanted into the backs of the mice in the control group one day before they started drinking the DSS aqueous solution. No substance was administered to normal mice (n=3).
[0049] iv) Evaluation of the effect of peptide administration The mice were weighed every day from the start of drinking the DSS aqueous solution until the removal of the large intestine. On the 10th day after the mice started drinking the DSS aqueous solution, the large intestine was removed from the mice and the colon length was measured.
[0050] (2) Results i) Weight change The changes in mouse body weight over the test period are shown in Figure 7 (see "Water" for normal mice, "DSS+PI5 saline" for the control group, and "DSS+PI5 1-44" for the HMGB1 peptide (1-44) administration group). The body weight of the IBD model mice (control group and HMGB1 peptide (1-44) administration group) decreased over the days, and was smaller than that of normal mice on the 10th day of drinking DSS water. In the HMGB1 peptide (1-44) administration group, weight loss was suppressed compared to the control group, and body weight on the 10th day of drinking DSS water was larger than that of the control group.
[0051] ii) Colon length As shown in Figure 8, under conditions in which the colon length of the control group of IBD model mice was shorter than that of normal mice, the colon length of the HMGB1 peptide (1-44) administration group was longer than that of the control group (see "Water" for normal mice, "DSS+PI5 saline" for the control group, and "DSS+PI5 1-44" for the HMGB1 peptide (1-44) administration group). These results indicate that colon shortening in DSS-induced colitis, an IBD model, was suppressed by administration of HMGB1 peptide (1-44).
[0052] Comparative Example 1 Administration of mesenchymal stem cells (MSCs) in inflammatory bowel disease models
[0053] In recent years, attempts have been made to use mesenchymal stem cells extracted from the body in the treatment of inflammatory bowel disease. Meanwhile, the present inventors have previously found that HMGB1 peptide (1-44) has the effect of mobilizing mesenchymal stem cells in bone marrow into peripheral blood. Therefore, the following experiment was carried out to compare the effects of administration of mesenchymal stem cells and administration of HMGB1 peptide (1-44).
[0054] (1) Materials and methods i) Drugs and Mice The preparation of the DSS aqueous solution and the HMGB1 peptide (1-44), and the generation of inflammatory bowel disease model mice were carried out in the same manner as in Example 1.
[0055] ii) Administration of mesenchymal stem cells IBD model mice prepared as described in Example 1 were divided into a mesenchymal stem cell (MSC) administration group (n=3) and a control group (n=3). Bone marrow was collected from the femur of C57BL / 6 mice (6-8 weeks old, male) and cultured in MesenCult (商標) Mesenchymal stem cells were obtained as adherent colonies by culturing on a plastic plate using MSC Basal Medium (Mouse) (manufactured by STEMCELL Technologies, containing 10 nM rock inhibitor and MesenPure). On the fifth day after drinking DSS, the mesenchymal stem cells after three passages were suspended in PBS and diluted to 1 × 10 6 The concentration was adjusted to cells / mL, and 100 μL was administered intraperitoneally to the mice in the MSC-administered group. Mice in the control group were administered 100 μL of PBS intraperitoneally on the fifth day after the start of DSS drinking. No substance was administered to normal mice (n=3).
[0056] iii) Evaluation of the effects of mesenchymal stem cell administration The body weight of each mouse was measured every day until the 9th day after starting to drink the DSS aqueous solution.
[0057] (2) Results Figure 9 shows the changes in mouse body weight over the test period (see "Water" for normal mice, "DSS+PBS" for the control group, and "DSS+MSCs" for the MSC-administered group). The body weight of the IBD model mice (control and MSC-administered groups) decreased over the days. There was no difference in body weight change between the MSC-administered group and the control group, and no improvement effect was observed due to MSC administration.
[0058] Under the conditions of this comparative example, administration of mesenchymal stem cells did not suppress weight loss in inflammatory bowel disease model mice, but HMGB1 peptide (1-44) was effective in improving symptoms such as weight loss in inflammatory bowel disease model mice created under similar conditions. Based on this, it is expected that the peptide of the present application will be effective even for patients with inflammatory bowel disease for whom administration of mesenchymal stem cells is not effective. [Industrial Applicability]
[0059] Pharmaceutical compositions containing the peptides of the present application are expected to be of great benefit to patients with inflammatory bowel disease for which existing therapeutic agents do not provide sufficient efficacy.
[0060] Sequence information SEQUENCE LISTING <110> StemRIM Inc. Osaka University <120> An agent for the treatment of inflammatory bowel disease <150> US 62 / 593,310 <151> 2017-12-01 <150> JP 2018-020686 <151> 2018-02-08 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 44 <212> PRT <213> Artificial sequence <220> <223> An artificially synthesized peptide sequence <400> 1 Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr 1 5 10 15 Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro 20 25 30 Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys 35 40 <210> 2 <211> 215 <212> PRT <213> Homo sapiens <400> 2 Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr 1 5 10 15 Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro 20 25 30 Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg 35 40 45 Trp Lys Thr Met Ser Ala Lys Glu Lys Gly Lys Phe Glu Asp Met Ala 50 55 60 Lys Ala Asp Lys Ala Arg Tyr Glu Arg Glu Met Lys Thr Tyr Ile Pro 65 70 75 80 Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys 85 90 95 Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Tyr Arg Pro Lys 100 105 110 Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys 115 120 125 Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr 130 135 140 Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala 145 150 155 160 Ala Tyr Arg Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val 165 170 175 Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu Glu Asp Glu Glu 180 185 190 Asp Glu Glu Asp Glu Glu Glu Glu Glu Asp Glu Glu Asp Glu Asp Glu 195 200 205 Glu Glu Asp Asp Asp Asp Glu 210 215 <210> 3 <211> 648 <212> DNA <213> Homo sapiens <400> 3 atgggcaaag gagatcctaa gaagccgaga ggcaaatgt catcatatgc attttttgtg 60 caaacttgtc gggaggagca tagagag cacccagatg cttcagtcaa cttctcagag 120 ttttctaaga agtgctcaga gaggtggaag accatgtctg ctaaagagaa aggaaattt 180 gagatatgg aaagcgga caagccccgt ttgaagag aaatgaaac ctatatccct 240 cccaaagggg agacaaaaaa gaagttcaag gatcccaatg cacccaagg gcctccttcg 300 gccttcttcc tcttctgctc tgagtatcgc ccaaaatca aaggaaca tcctggcctg 360 tccattggtg atgttgcgaa gaaactggga gagatgtgga atacactgc tgcagatgac 420 aagcagcctt atgaaagaa ggctgcgaag ctgaggaaa atacgaaaa ggatattgct 480 gcatatcgag ctaaaggaaa gcctgatgca gcaaaaagg gagttgtcaa ggctgaaaaa 540 agghaaaaaaaaaaagaagagagagagagagagagagagagagagagagagagagagagagagagagagaga 600 Gagagagagagagagagagagagagagagagaatgaata 648
Claims
1. A pharmaceutical composition for preventing and / or treating a non-specific inflammatory bowel disease, comprising a peptide according to any one of the following (a) to (c), wherein the non-specific inflammatory bowel disease is ulcerative colitis or Crohn's disease: (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which 1 to 4 amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
2. 2. The pharmaceutical composition of claim 1, wherein the non-specific inflammatory bowel disease is ulcerative colitis.
3. 2. The pharmaceutical composition of claim 1, wherein the non-specific inflammatory bowel disease is Crohn's disease.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which 1 to 3 amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 93% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
5. The pharmaceutical composition according to any one of claims 1 to 3, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which one or two amino acids are substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 95% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
6. The pharmaceutical composition according to any one of claims 1 to 3, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which one amino acid is substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 97% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
7. 4. The pharmaceutical composition according to claim 1, wherein the peptide is a peptide consisting of the amino acid sequence set forth in SEQ ID NO:
1.
8. A pharmaceutical composition for suppressing weight loss or damage to the intestinal mucosa in a patient with non-specific inflammatory bowel disease, comprising any one of the peptides (a) to (c) below, wherein the non-specific inflammatory bowel disease is ulcerative colitis or Crohn's disease: (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which 1 to 4 amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
9. The pharmaceutical composition according to claim 8, wherein the non-specific inflammatory bowel disease is ulcerative colitis.
10. The pharmaceutical composition of claim 8, wherein the non-specific inflammatory bowel disease is Crohn's disease.
11. The pharmaceutical composition according to any one of claims 8 to 10, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which 1 to 3 amino acids have been substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 93% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
12. The pharmaceutical composition according to any one of claims 8 to 10, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which one or two amino acids are substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 95% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
13. The pharmaceutical composition according to any one of claims 8 to 10, wherein the peptide is any one of the following peptides (a) to (c): (a) a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1; (b) a peptide having an amino acid sequence in which one amino acid is substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO: 1; and (c) A peptide having an amino acid sequence that has 97% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having the same function as the peptide having the amino acid sequence set forth in SEQ ID NO:
1.
14. The pharmaceutical composition according to any one of claims 8 to 10, wherein the peptide is a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Citation Information
Patent Citations
Peptide for inducing regeneration of tissue and use thereof
WO2012147470A1
Novel method for treating cardiac infarction using HMGB1 fragment
WO2014065347A1
Novel method for treating spinal cord injury using HMGB1 fragment
WO2014065348A1
